Get the Stockscreener App
2.38
0.21%
-0.005
Edesa Biotech Inc stock is traded at $2.38, with a volume of 10,968.
It is down -0.21% in the last 24 hours and down -26.77% over the past month.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
See More
Previous Close:
$2.385
Open:
$2.49
24h Volume:
10,968
Relative Volume:
0.01
Market Cap:
$16.64M
Revenue:
-
Net Income/Loss:
$-7.72M
P/E Ratio:
-0.9017
EPS:
-2.6394
Net Cash Flow:
$-6.25M
1W Performance:
+2.59%
1M Performance:
-26.77%
6M Performance:
-45.53%
1Y Performance:
-45.03%
1-Day Range:
$2.34
$2.49
1-Week Range:
$2.2001
$2.55
52-Week Range:
$1.55
$5.59
Edesa Biotech Inc Stock (EDSA) Company Profile
Name
Edesa Biotech Inc
Sector
Industry
Phone
(905) 475-1234
Address
100 SPY COURT, MARKHAM, ON
Compare EDSA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EDSA
Edesa Biotech Inc
|
2.38 | 16.64M | 0 | -7.72M | -6.25M | -2.6394 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Edesa Biotech Inc Stock (EDSA) Latest News
H.C. Wainwright maintains $21 target on Edesa Biotech shares By Investing.com - Investing.com South Africa
Edesa Biotech completes US$15 million private placement - Fasken
Edesa Biotech files to sell 7.81M common shares for holders - MSN
Zacks Small Cap Boosts Earnings Estimates for Edesa Biotech - Defense World
EDSA: Raises 15 Million to Advance EB06 - Smartkarma
EDSA: Raises $15 Million to Advance EB06… - Yahoo Finance
Biotech Stocks To Keep An Eye OnFebruary 13th - MarketBeat
Biotech Stocks To Keep An Eye On – February 13th - Defense World
Edesa Biotech Reports Fiscal 1st Quarter 2025 Results - GlobeNewswire
Edesa Biotech Advances Vitiligo Treatment Amidst Solid Financial Backing - TipRanks
Edesa Biotech Inc. (EDSA) reports earnings - Quartz
Edesa Biotech Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Edesa Biotech, Inc. SEC 10-Q Report - TradingView
Edesa Biotech Reports Q1 2025 Financial Results and Updates on EB06 Development for Vitiligo Treatment - Nasdaq
Edesa's Q1 Report Reveals Major Vitiligo Drug Progress: $15M Cash Injection Fuels FDA Push - StockTitan
US Penny Stocks To Watch In February 2025 - Simply Wall St
Edesa Biotech secures $15 million for clinical program By Investing.com - Investing.com Nigeria
Novartis to acquire Anthos Therapeutics for up to $3.1 billion - MSN
Edesa Biotech, Inc. announced that it has received $14.999992 million in funding from Velan Capital Investment Management LP and another investor - Marketscreener.com
H: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
Edesa Biotech Inc (EDSA) Stock: A Comprehensive 52-Week Review - The InvestChronicle
Dow Jumps Over 100 Points; Deere Posts Upbeat Earnings - Benzinga
Stock market news: Moleculin Biotech +583.33%, Cloudastructure +105.68% among top gainers during midday trading - Business Upturn
Nasdaq Surges 150 Points; Cisco Earnings Top Views - Benzinga
Edesa Biotech shares jump on $15M private placement - MSN
Edesa Biotech (EDSA) Sees Sharp Stock Increase After Equity News - Stocks Telegraph
Stock market today: Moleculin Biotech +388.10%, Alpha Modus Holdings +156.52% among top gainers in early trading - Business Upturn
MAXONA Pharmaceuticals Completes Phase 1 Trials for Breakthrough Pain Therapy - MSN
US Stocks Edge Higher; Producer Prices Increase In January - Benzinga
Truist maintains Buy on Genmab stock, price target at $50 - MSN
Edesa Biotech announces $15 million private placement - MSN
Information Provided Pursuant to Early Warning Requirements with Respect to Par Nijhawan and Velan Capital - Financial Post
Edesa Biotech Announces $15.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules - Marketscreener.com
Edesa Biotech secures $15 million for clinical program - Investing.com India
Edesa Biotech Secures $15 Million in Private Placement to Advance Clinical Programs - TipRanks
Edesa Biotech announces $15M private placement priced at-the-market - TipRanks
Edesa Biotech Secures $15 Million for CXCL10 Antibody Program - TipRanks
Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules - GlobeNewswire
Major Funding Alert: Edesa's $15M Deal Fuels Breakthrough Vitiligo Drug Development - StockTitan
Dallas City Council approves planning deal for 2026 World Cup - MSN
Mawson Finland announces private placement for up to C$5M - MSN
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? - MSN
Jabil acquires CDMO Pii to support drug development customers - MSN
Obesity drug developer Aardvark files for IPO - MSN
EDSA: IND Expected in 2025 for EB06 for the Treatment of Vitiligo - Research Tree
EDSA: IND Expected in 2025 for EB06 for the Treatment of Vitiligo… - Yahoo Finance
Edesa Biotech Announces $4.36 million Registered Direct Offering - ACCESS Newswire
Is Raytheon the Best Defense and Aerospace Stock to Own in 2025? - The Globe and Mail
Edesa Biotech, Inc. (NASDAQ:EDSA) Short Interest Update - Defense World
EDSA Stock Touches 52-Week Low at $1.69 Amid Market Challenges - Investing.com
Edesa Biotech Inc Stock (EDSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):